Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-15
1998-04-14
Jacobson, Dian C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514822, 530380, 530381, 530829, C07K 14745, A61K 3817, A61K 3836
Patent
active
057391017
ABSTRACT:
A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.
REFERENCES:
patent: 4966852 (1990-10-01), Wun et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5504067 (1996-04-01), Morrissey
Harrison's Principles of Internal Medicine, 11th edition p. 1478.
Bach, Ronald R., "Initiation of Coagulation by Tissue Factor" CRC Critical Reviews in Biochemistry 23(4):339-368 (1988).
Fisher, K.L. et al., "Cloning and Expression of Human Tissue Factor cDNA" Thrombosis Research 48(1):89-99 (1987).
Krangel et al., "Characterization of B Lymphoblastoid Cell Line Mutant that Secretes HLA-A2" J. Immunol. 132(6):2984-2991 (1984).
Mason et al., "Activin B: Precursor Sequences Genomic Structure and in Vitro Activities" Molecular Endocrinology 3(9):1352-1358 (1989).
O'Brien et al., "Factor VIII-Bypassing Activity of Bovine Tissue Factor Using the Canine Hemophilic Model" J. Clin. Invest. 82:206-211 (1988).
Paborsky et al. Biochemistry 28(20):8072-8077 (1989).
Roy et al. Journal of Biological Chemistry 266(8):4665-4668 (1991).
Sakai et al. Journal of Biological Chemistry 264(17):9980-9988 (1989).
Spicer et al., "Isolation of cDNA clones coding for human tissue factor: Primary structure of the protein and CDNA" Proc. Natl. Acad. Sci. USA 84(15):5148-5152 (1987).
Taylor, FB Jr et al., "Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody" Circ-Shock 33(3):127-134 (Mar. 1991).
Roy Soumitra
Vehar Gordon A.
Genentech Inc.
Jacobson Dian C.
Kubinec Jeffrey S.
LandOfFree
Tissue factor mutants useful for the treatment of myocardial inf does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue factor mutants useful for the treatment of myocardial inf, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue factor mutants useful for the treatment of myocardial inf will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-634551